Werth VP, Hejazi E, Pena SM, et al. A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis. ACR 2017, abstract 7L.
Stoppen en herbehandelen met etanercept bij nr-axSpA: resultaten van RE-EMBARK
jun 2023 | Spondyloartritis